The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Fact checked by Jennifer Klump Key Takeaways The FDA approved the obesity drug Wegovy as a treatment for people with MASH ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

The stock market is abuzz as shares of Novo Nordisk (NVO) experience a notable rise following the recent approval of its weight loss medication, Wegovy, by the U.S. Food and Drug Administration (FDA) ...

Shares of Novo Nordisk (NVO) are making headlines as they rise sharply following the U.S. Food and Drug Administration's (FDA) recent approval of Wegovy for treating metabolic-associated ...

The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Recent developments in weight-loss treatments have impacted the market significantly. Viking Therapeutics' new pill showed ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...